Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carol Pappas

Neurology St Petersburg, FL Medical Doctor

NPI 1659442101 CMS profile 211294

2191 9Th Ave N, Suite 230, St Petersburg, FL 33713

Open in the dashboard

General payments

$80,358

346 records reported · program years 2019–2025

Research payments

$23,371

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,548 paid to institutions, not to them · program years 2023–2024

Through program year 2025, Carol Pappas of St Petersburg, FL is reported in the CMS Open Payments database as having received $80,358 across 346 general payments and $23,371 in research payments paid to them. Separately, studies naming them as principal investigator received $10,548 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,306 43
2024 General $4,533 32
2023 General $16,720 48
2022 General $12,581 62
2022 Research $23,371 2
2021 General $15,289 56
2020 General $6,365 31
2019 General $22,565 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Pappas
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Carol Pappas were reported at $2,306. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Carol Pappas Neurology median Middle half National median
2019 $22,565 $474 $118–$2,177 $163
2020 $6,365 $367 $82–$2,309 $114
2021 $15,289 $438 $104–$2,547 $132
2022 $12,581 $442 $103–$2,388 $149
2023 $16,720 $464 $119–$2,312 $160
2024 $4,533 $468 $119–$2,323 $164
2025 $2,306 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $58,491 104 payments
  2. Neurocrine Biosciences, Inc. $12,629 31 payments
  3. Amneal Pharmaceuticals LLC $5,505 12 payments
  4. Biogen, Inc. $641 34 payments
  5. ACADIA Pharmaceuticals Inc $300 18 payments
  6. Sunovion Pharmaceuticals Inc. $297 20 payments
  7. Lilly USA, LLC $253 11 payments
  8. Abbott Laboratories $239 4 payments
  9. US WorldMeds, LLC $235 22 payments
  10. UCB, Inc. $205 9 payments
  11. Other $1,561 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,131 30 payments
  2. Consulting Fee $7,350 5 payments
  3. Travel and Lodging $6,549 30 payments
  4. Food and Beverage $5,925 276 payments
  5. Honoraria $3,961 2 payments
  6. Education $1,441 3 payments
Products named General payments · program years 2019–2025
  1. DUOPA $56,948 94 payments
  2. Ongentys Neuropsychiatry $12,321 18 payments
  3. ONGENTYS Neurology $2,893 5 payments
  4. ONGENTYS Neurology $1,631 1 payment
  5. ONGENTYS 50MG CAPSULES 30 $932 1 payment
  6. VUMERITY $369 19 payments
  7. INGREZZA $335 18 payments
  8. APTIOM $260 16 payments
  9. INFINITY $239 4 payments
  10. NUPLAZID $177 10 payments
  11. Other $3,380 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $23,371 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,628

Median for Neurology: 833

Drug cost

$484,026

Median for Neurology: $202,670

Branded share of claims

38.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 26 $133,123
Ongentys Opicapone Brand 61 $81,403
Austedo Xr Deutetrabenazine Brand 12 $69,793
Neupro Rotigotine Brand 30 $52,724
Eliquis Apixaban Brand 40 $33,509
Aptiom Eslicarbazepine Acetate Brand 17 $25,227
Memantine Hcl Er Memantine Hcl Brand 112 $17,895
Rivastigmine Generic 40 $9,408
Rytary Carbidopa/Levodopa Brand 16 $8,632
Ropinirole Er Ropinirole Hcl Brand 27 $7,043

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$157,406

Medicare's payments for the services billed

Medicare patients

544

Average age 78

Services billed

1,725

298 women, 246 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 45%
Ischemic heart disease 44%
Chronic kidney disease 42%
Atrial fibrillation 35%
Diabetes 33%
Alzheimer's or dementia 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ONGENTYS
  • Amneal Pharmaceuticals LLC $2,893
$2,893 61 —
ONGENTYS 50MG CAPSULES 30
  • Amneal Pharmaceuticals LLC $932
$932 61 —
INGREZZA
  • Neurocrine Biosciences, Inc. $150
$150 — —
DUOPA
  • AbbVie, Inc. $133
$133 — —
VUMERITY
  • Biogen, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record